Health
Health care sector gears up for U.S. reform
NEW YORK (Reuters) - Drug makers, insurers and other health care companies are preparing for possibly dramatic changes to the U.S. health care system as Democrats increase their power in Washington next year.
More money and strong leader wanted at FDA
NEW YORK (Reuters) - Drug makers are calling for steady leadership, political independence and a boost in funding to improve the climate at the U.S. Food and Drug Administration under President-elect Barack Obama.
Pharma overhaul under way ahead of challenges
NEW YORK (Reuters) - Leaders of the world's largest drug makers are all under the hood working to overhaul a rusty business model, even as they differ over the right new parts.
Daiichi confident of Effient approval
NEW YORK (Reuters) - Daiichi-Sankyo's top U.S. executive expressed confidence that the blood clot preventer it is developing with Eli Lilly & Co will soon win U.S. approval, and said the sales force for the medicine was champing at the bit to get started. | Video
Walgreen makes Times Square return as it revamps
CHICAGO (Reuters) - Walgreen Co has more than 6,500 drugstores across the United States, but only one of them can help the chain reach billions of people, even if they never step inside. | Video
Pharmaceuticals can't escape recessionary chill
NEW YORK (Reuters) - It may still carry a defensive tag, but the pharmaceuticals industry won't escaped unscathed as economies around the world are pitched into recession.
Is biotech really such a bargain?
NEW YORK (Reuters) - Cash-strapped biotechs may be hoping Big Pharma rides to the rescue, but they shouldn't count on it.
Pfizer pegs growth to overseas, older drugs
NEW YORK (Reuters) - Pfizer Inc's top executive is counting on higher sales in emerging markets and revenue from older medicines to generate enough revenue in the next three years to help offset an expected plunge in sales of its top selling Lipitor cholesterol drug.
Pfizer, others still chasing obesity drugs
NEW YORK (Reuters) - After pulling the plug on an experimental obesity drug from a troubled class of medicines, Pfizer Inc's Chief Executive Jeff Kindler said the world's largest drug maker would continue to pursue treatments for the emerging health crisis.
Pfizer CEO: Independence needed at FDA
NEW YORK (Reuters) - The U.S. Food and Drug Administration was hurt by turnover at the top during the George W. Bush administration and needs a strong, independent leader, Pfizer Inc Chief Executive Jeff Kindler said on Thursday.
Quotes from the Health Summit: Thursday
NEW YORK (Reuters) - Following are selected quotes from executives speaking at the Reuters Health Summit, being held in New York through November 20.
Speakers
| Summit | Date | Category |
|---|---|---|
| Islamic Banking and Finance | Feb 15 - 18 | Country Summits |
| Travel and Leisure | Feb 22 - 24 | Hotels/Casinos |
| Private Equity and Hedge Funds | Mar 1 - 3 | Financial Services/Exchanges |
| Global Mining and Steel | Mar 8 - 10 | Mining |
| Food and Agriculture | Mar 15 - 18 | Mining |
| Canadian Oil Sands | Mar 22 - 23 | Energy |
| Funds | Mar 23 - 24 | Financial Services/Exchanges |
| Global Exchanges and Trading | Mar 29 - 31 | Financial Services / Exchanges |
| Financial Regulation | Apr 26 - 29 | Financial Services / Exchanges |





